In this episode of Biopeak Live, hosts Prof Deepak Saini and Mr Prashanth Prakash are joined by Prof Matt Kaeberlein for a wide-ranging conversation on the current state and future of longevity science.Matt reflects on his journey from academia into entrepreneurship and the challenges that shaped projects like the Dog Aging Project and Ora BiomedicalThe discussion explores mTOR biology, Rapamycin, caloric restriction, biological clocks, AI-driven discovery, and the limitations of the “hallmarks of aging” framework.Matt also shares his views on supplement hype, the promise and pitfalls of biological age testing, and why large-scale unbiased discovery science may be key to unlocking the next era of longevity research.Timestamps00:00 – Introduction01:03 – Matt Kaeberlein’s journey into aging research04:09 – Early aging biology research06:47 – Academia vs startups11:31 – mTOR and Rapamycin14:37 – Hallmarks of Aging15:30 – AI and aging iology21:20 – Discovery science and intervention screening24:23 – WormBot and Million Molecule Challenge29:17 – Caloric restriction and combination therapies34:38 – Rapamycin trials in India41:16 – Longevity biomarkers and clinical trials47:34 – Preventative longevity medicine50:30 – Supplements and longevity hype54:29 – Biological clocks and epigenetic testingAbout Matt KerberleinMatt Kaeberlein, Professor at the University of Washington, and Co-Director of the Dog Aging Project. His research focuses on understanding the biological mechanisms of aging and developing interventions to improve healthspan in both humans and companion animals.He has published over 250 scientific papers in aging biology and is a Fellow of the AAAS, AGE, and GSA. Dr. Kaeberlein has received several major awards in gerontology and previously served as Director of the University of Washington Healthy Aging and Longevity Research Institute and the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging.